secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2025-01-22T23:59:59+00:00
Accession:  0000200406-25-000003
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ Q4 net earnings down 17%, revenue up 5.3% to $22.52B; adjusted EPS $2.04
----------------------------------------------------------------------------

- Q4 sales $22.52B, +5.3% YoY; net earnings $3.43B, -17% from $4.13B; diluted EPS $1.41.
- Adjusted net earnings $4.95B, adjusted EPS $2.04, down 10.9% from $2.29.
- Innovative Medicine (ex-COVID) sales $14.33B (+4.8%); MedTech sales $8.19B (+6.7%).
- R&D expense rose 18.3% to $5.30B; operating margin contracted to 17.3% from 22.6%.
- Full-year sales $88.82B, +4.3% vs $85.16B; ex-COVID sales +5.5%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040625000003/0000200406-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040625000003/jnj-20250122.htm
  HTML page:      https://secwatch.observer/filing/0000200406-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer